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A B S T R A C T
The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health
Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur
annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the
emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore,
new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant
minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB.
Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises
the available data on BDQ resistance, describes its antimicrobial properties, and provides new
perspectives on clinical use of this novel anti-TB agent.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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. Introduction
Tuberculosis (TB), an ancient infectious disease caused by
ycobacterium tuberculosis and other closely related species, with
n incidence of approximately 500 000 TB cases and an estimated
wo million to three million deaths worldwide annually, is ranked
s the second leading cause of death worldwide among infectious
iseases [1–3]. Although overall TB rates are on the decline, the
revalence of multidrug-resistant TB (MDR-TB) and, more recently,
xtensively drug-resistant TB (XDR-TB) is increasing and spreading
t an alarming rate, which should be held in consideration [2,4].
According to epidemiological results, TB is more deadly than
ther infectious diseases such as acquired immune deficiency
yndrome (AIDS) and malaria. Despite a 22% global decline in TB
eaths between 2000 and 2015, it is still one of the top 10 causes of
eath worldwide [5]. Also, on the eve of the first turning point in
020, the World Health Organization (WHO) still reports TB to
ave the highest mortality rate of any infectious disease
orldwide, even surpassing HIV/AIDS and causing 1–5 million
eaths in 2018 [6]. According to WHO reports, the prevalence of
DR-TB varies from 0% to 65% in different countries [7]. In fact, the
revalence of TB mortality varies from <5% in some countries to
20% in the African Region [8]. Approximately two-thirds of MDR-
B cases are currently reported in China, India and Russia. Of the
pproximately half a million people who developed MDR-TB in
018, only the equivalent of one in three cases were enrolled in
reatment [6]. In 2016, there were approximately 10.4 million new
ases of TB worldwide, of which 1.7 million died from TB, and
pproximately 600 000 recent cases of MDR-TB have appeared
orldwide, leading to 240 000 deaths in 2017 [8]. According to
ecent WHO reports, Europe and seven countries with heavy
urdens (Kenya, Lesotho, Myanmar, Russia, South Africa, Tanzania
nd Zimbabwe) are reaching a turning point in 2020. The incidence
nd mortality are also declining relatively rapidly in the WHO
frican Region [6]. Therefore, efforts in the discovery of novel and
ore effective anti-TB agents are urgently required. Bedaquiline
BDQ), previously known as TMC207, R207910 or compound J, is a
ew last-line anti-TB drug belonging to the diarylquinoline group.
t was first discovered by Andries et al. in 2005 [9]. They
nvestigated different chemical compounds in order to select
rototypes and to examine their inhibitory effect on multiple-cycle
rowth of Mycobacterium smegmatis by whole-cell assay. From
hese prototypes, Andries et al. indicated BDQ as the lead
ompound among a series of diarylquinolines with laboratory
ffects on several mycobacteria, especially M. tuberculosis [10,11].
his new anti-TB drug with a novel mechanism of action is the first
role in the treatment of MDR-TB. However, considering limited
data obtained from phase two trials, final approval remains
contingent on confirmatory phase three trials. Following promis-
ing findings, BDQ under the trade name Sirturo1, is now the first
new FDA-approved anti-TB drug in Europe and the USA for use in
MDR-TB therapy [12,13]. Despite the outstanding advantages of
BDQ as a very promising anti-TB drug, there is a black box warning
relating to the drug’s effectiveness and safety [1,14,15].
2. Antimicrobial properties of bedaquiline
2.1. Structure of bedaquiline (Fig. 1)
BDQ falls into the class of compounds known as diarylquino-
lines, which belongs to a novel category of anti-TB drugs. BDQ
contains a quinolinic central heterocyclic nucleus with alcohol and
amine side chains that are responsible for its anti-TB activity
[16,17]. The structural formula of BDQ shows two major
components: (i) a hydrophobic part containing N(CH3)2, which
has a vital role in binding to the ATP synthase; and (ii) an H2-
bonding acceptor/donor that provides stability. However, the anti-
TB activity of BDQ is attributed to the diarylquinoline ring, the side
chain with the N,N-dimethyl amino terminus, the hydroxyl group
and the naphthalene moiety. According to previous reports, the
molecular weight of BDQ is approximately 555.51 Da with a
molecular formula of C32H31BrN2O2C4H4O4 [18–20]. It is chemi-
cally compounded with fumaric acid (1:1) as BDQ fumarate. BDQ as
an enantiopure compound harbouring two adjacent chiral centres
was purified from a mixture of four isomers using high-
performance liquid chromatography (HPLC). Some inactive ingre-
dients including croscarmellose sodium, lactose monohydrate,
polysorbate 20, microcrystalline cellulose, hypromellose 2910
(15 mPa s), colloidal silicon dioxide, corn starch, magnesium
stearate, purified water are reported in the drug BDQ [9,21,22].
Regarding the structural complexity of BDQ, and in order to
improve the anti-TB effect of this drug as well as its pharmacoki-
netic/pharmacodynamic properties, extensive research projects
have focused on reducing the complexity of the structure while
maintaining its anti-TB activity. Although these research activities
led to the identification of new related compounds, none of these
has progressed to clinical evaluation. Therefore, there is still a need
for identification of BDQ analogues to deliver potential new leads
[23,24] .
2.2. Mechanism of action of bedaquilinerug in a new class approved to treat MDR-TB and XDR-TB since the
pproval of rifampicin in 1971 in the USA [2]. The US Food and Drug
dministration (FDA) granted BDQ accelerated approval based on
hase 2 data and a reduction in the time to sputum smear and
ulture conversion among MDR-TB patients treated with BDQ,
hich highlighted an advantage of this drug in addition to its key4
Although it is well established that BDQ is closely related to the
fluoroquinolones, unlike the fluoroquinolones it displays no
inhibitory effects on DNA gyrase and its mechanism of action
differs. BDQ is the only FDA-approved anti-TB drug that targets
adenosine triphosphate (ATP) by inhibiting the proton pumping
mechanism [25]. ATP is produced by ATP synthase and is a vital9
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mycobacteria in the extracellular or intracellular form, replicating
or non-replicating, and active or dormant. ATP synthase, a
ubiquitous key enzyme located in the inner membrane of
mycobacterial mitochondria, is able to generate energy to fuel
the catabolic and anabolic reactions of growing mycobacterial cells
[9,18,23,26]. This complex enzyme is composed of two sectors,
cytoplasmic sector F1 (five subunits a3, b3, g, d and e) and
membrane sector F0 (three subunits a, b2 and c10-15). The c
subunits of F0 are arranged in the form of disks and function as an
ion-conducting pathway, and F1 contains three catalytic sites that
combine one ADP with a phosphate (Pi) to form ATP. Evidence
showed that the proton motive force through F0 reinvigorates the
rotation of the cylindrical ring of subunits c and results in coupled
rotation of the catalytic b subunit of F1 domain resulting in ATP
synthesis [9,23,27]. It is well documented that BDQ can bind to the
oligomeric/proteolipidic subunit c in the F0 domain of the ATP
synthase complex and prevent its function. BDQ has been also
shown to be able to inhibit mycobacterial F-ATP synthase via
targeting the enzyme’s e subunit in addition to binding to its c
subunit [9,23]. The inhibitory effect of BDQ on ATP synthase is
specific for mycobacteria. It should be noted that the ATP synthase
complex in humans possesses 20 000-fold lower sensitivity to BDQ
compared with M. tuberculosis, indicating unlikely target-based
toxicity and interaction with human ATP synthase [23,28].
2.3. Spectrum of activity of bedaquiline
Different studies on BDQ indicated that it has potent
antimycobacterial activity against M. tuberculosis and the majority
of nontuberculous mycobacteria (NTM), both rapidly and slowly
growing [29]. BDQ showed a selective effect against a wide variety
of dormant and actively replicating mycobacteria as well as non-
pathogenic organisms such as M. smegmatis [18,30,31]. Some
mycobacterial species such as Mycobacterium xenopi, Mycobacteri-
um shimoidei and Mycobacterium novocastrense are naturally
resistant to BDQ, with minimum inhibitory concentrations (MICs)
of >8 mg/L. However M. smegmatis mutant strains and some of TB
strains have developed resistance to BDQ. Interestingly, an
Mycobacterium flavescens strain in which alanine 63 in AtpE was
replaced by methionine that was completely resistant to BDQ was
also reported [24,32,33]. In a 2005 study by Andries et al., the
activity of BDQ against M. tuberculosis isolates compared with
3. Bedaquiline resistance
A major problem in patients with TB is the prolonged duration
of therapy and multiple anti-TB regimens that may lead to acquired
drug resistance and its dissemination among mycobacteria [12,29].
Further treatment may potentially reduce antibiotic-susceptible
isolates, allowing highly resistant isolates to become predominant.
Increasing resistance to anti-TB agents and emerging MDR and
XDR-TB strains is a major health threat in numerous regions
globally and should be considered. Since the introduction of BDQ
for the treatment of MDR-TB, resistance to this antibiotic emerged
[34,35]. At the end of 2015, 50 countries described having received
BDQ for treatment of more than 2500 patients. Based on WHO
reports, at the end of 2017, 68 countries described having
introduced or begun using BDQ for the treatment of MDR/XDR-
TB. Although BDQ is a recommended drug for increasing treatment
efficacy of MDR-TB, inadequate or improper use of BDQ may lead to
the rapid emergence of resistant strains [34]. The WHO has also
suggested that the emergence of resistance to BDQ may be caused
by improper use of this antibiotic, which should be carefully
monitored [36].
The WHO clearly emphasised the improvement of precise and
reproducible drug susceptibility testing for BDQ and proposed that
if there is no specific drug susceptibility testing, serial MIC
determinations should be applied for monitoring BDQ resistance.
Several studies around the world have shown controversies in the
definition of BDQ resistance. Unfortunately, up to now, stand-
ardised drug susceptibility testing for BDQ has not been developed
and agreed upon [13,34,36]. According to the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines, MIC
breakpoints for BDQ are defined as follows: susceptible, 0.25 mg/
L; and resistant, >0.25 mg/L [29,37].
3.1. Mechanisms of resistance to bedaquiline
Published data regarding antibiotic resistance in TB have
described two main mechanisms: (i) primary or transmitted drug
resistance; and (ii) secondary or acquired drug resistance [33,38].
Several investigators strongly emphasise that resistance mecha-
nisms are mainly linked to chromosomal mutations [39,40]. To
date, known molecular mechanisms underpinning resistance to
BDQ are divided in three categories [10,37]. The first mechanism is
related to mutations in the atpE gene that encodes a transmem-
brane protein of F1/F0-ATP synthase and was previously reported
by Andries et al. [10]. The likelihood of resistance mutations to BDQ
is 5  10–7 at 4-fold the MIC and 5  10–8 at 8-fold the MIC. By
sequencing the atpE gene in in vitro-selected M. tuberculosis
isolates upon exposure to BDQ, six distinct amino acid substitu-
tions and mutations in the subunit c forming the C ring in the ATP
synthase were revealed, including replacement of Asp28 → Gly,
Asp28 → Ala, Leu59 → Val, Glu61 → Asp, Ala63 → Pro and
Ile66 → Met, which prevent BDQ from binding to its target, the c
subunit, thus maintaining H+ transfer and ATP synthesis. These
mutations are able to increase the MIC of BDQ by 10–133-fold.
Mutations causing the substitution Ala63 → Pro resulted in a 133-
fold increase in the MIC (4 mg/L) compared with wild-type M.
tuberculosis H37Rv. The mutations Glu61 → Asp, Ile66 → Met and
Asp28 → Gly resulted in a 16- to 33-fold increase in MIC, from 0.5 to
1 mg/L, compared with wild-type H37Rv. In M. tuberculosis mutant
strains, mutations causing the substitution Leu59 → Val caused a
Fig. 1. Structure of bedaquiline as the free base form.rifampicin and isoniazid was assessed. The authors indicated that
BDQ had greater potency than either rifampicin or isoniazid [9,10].
In a study by Chahine et al., it was demonstrated that the average
MIC of BDQ against MDR isolates of M. tuberculosis was 0.03 mg/L.
Overall, it can be inferred that BDQ is a narrow-spectrum antibiotic
whose activity that appears to be limited to mycobacteria [18].50small rise in the MIC (8-fold).
The amino acid substitution Asp28 → Ala in Mycobacterium
fortuitum mutants harbouring this mutation led to a 400-fold
increase in MIC, whereas it was caused a 32-fold increase in
Mycobacterium abscessus mutants. M. abscessus with the specific
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he MIC. Recently, two new substitutions (D28N and A63V) were
ound to be associated with increased BDQ MICs in clinical isolates
23,38]. In a recent study by Huitric et al. to identify point
utations in the atpE gene, 53 in vitro mutants were investigated
41]. They discovered five single point mutations (A28V, A63P,
66M, A28P and G61A) in the atpE gene in only 28% (15/53) of the
DQ-resistant isolates and no mutation was detected in atpE or
ven in the F0, F1 operons in the remaining 72% (38/53). This
nding strongly highlighted the possible existence of other
esistance mechanisms against BDQ that need to be explored.
dditionally, no resistant mutants were reported when exposed to
 mg/L.
It is noteworthy that some of NTM are inherently resistant to
DQ. This has been associated with replacement of the methio-
ine residue with an alanine amino acid in the 63rd position in
ubunit c. The second mechanism is related to mutations in
v0678 modulating expression of the MmpS5–MmpL5 efflux
ump. These mutations are identified in isolates upon in vitro
xposure to BDQ or clofazimine (CFZ) and in some of isolates of
atients treated with the BDQ [2], which resulted in a high 2- to 8-
old increase in the BDQ MIC and a 2- to 4-fold increase in the CFZ
IC. Drug efflux as a significant mechanism both in intrinsic and
cquired BDQ resistance has recently attracted much interest
mong microbiologists, pharmacologists and clinicians. Interest-
ngly, a study performed by Gupta et al. assessing the effect of
erapamil on efflux inhibition demonstrated an 8- to 16-fold
ecrease in their BDQ and CFZ MICs in the presence of verapamil
42].
Although efflux pumps contribute to BDQ and CFZ resistance by
educing the transmembrane potential, it was showed that
ddition of efflux pump inhibitors such as verapamil caused in a
- to 16-fold decrease in the MIC of BDQ and CFZ [43]. However in
nother study conducted in South Africa, all 12 isolates with a 4-
old increase in BDQ MIC had mutations in Rv0678, a transcrip-
ional repressor of the MmpS5–MmpL5 efflux pump [35].
artkoorn et al. also showed the role of Rv0678 gene mutations
n BDQ and CFZ cross-resistance, potentially restricting therapeutic
hoices [44]. Although the majority of Rv0678 mutants were
eported in patients treated with BDQ-containing regimens,
ecently some of researchers also reported these mutant strains
n patients without prior exposure to BDQ or CFZ [45].
Interestingly, Villellas et al. demonstrated a high frequency of
v0678 resistance-associated variants (RAVs) among MDR-TB
solates (23/347; 6.6%) [12]. Surprisingly, none of the patients
xcept for seven subjects had a history of exposure to either BDQ or
FZ. The occurrence of Rv0678 RAVs in MDR-TB strains was 9-fold
igher compared with non-MDR-TB isolates (0.7%) [12]. In a study
y Andries et al., a high prevalence of mutations in Rv0678 was also
eported (6.6%), suggesting the important role of this gene in
ncreasing the MICs of BDQ [10]. In another report, it was noted
hat mutation in Rv0678 was detected in five MDR-TB isolates and
his mutation persisted despite restriction in its use for over 1 year
46]. In a recent study, investigation of MDR-TB patient who
eceived BDQ for 6 months indicated that mutation in position 2
GTG → GCG) in Rv0678 that leads to impair function is responsible
or the high-level resistance observed [47]. Recent published
tudies described mutations in the Rv0678 regulator gene (2 T > C
eading to M1A) related to BDQ and CFZ resistance in a patient with
DR-TB [39,48].
low-level resistance to BDQ and cross-resistance to CFZ. Mutation
in pepQ led to a slight increase of 4-fold in BDQ and CFZ MICs.
These mutations act by reduction of the antibiotic effectiveness in
vivo but did not result in complete resistance. Accordingly, one
intriguing study in a murine TB model showed that a pepQ mutant
was virulent and less susceptible to BDQ and CFZ [39]. The results
obtained from this study explained that resistance mediated by
pepQ mutation may be related to higher antibiotic efflux, but this is
not linked to overexpression of mmpL5 and mmpS5. This
comprehensive report also demonstrated that pepQ dysfunction
is adequate for decreased susceptibility both in vitro and in vivo
[39,49].
3.2. Epidemiology of bedaquiline resistance
Since the recent administration of BDQ as an option for MDR-TB,
several thousands of people had received this drug around the
world [50]. Like other drugs, BDQ-resistant strains emerged pretty
quickly and increased concern about its future role in anti-TB
regimens. M. tuberculosis isolates acquire resistance to BDQ by
spontaneous chromosomal mutation in atpE (BDQ target), Rv0678
(transcriptional repressor of the MmpS5–MmpL5 efflux pump),
Rv0677c, pepQ (encoding an Xaa-Pro aminopeptidase) genes and
mutations in the intergenic region between Rv0678 (efflux pump
MmpL5) and Rv0677c (efflux pump MmpS5) that result in
suppression of ATP synthase inactivity [50,51].
Until now, a few patients with BDQ resistance have been
described. In 2014, the first case of a MDR-TB patient with a BDQ-
resistant isolate was reported. After 24 months of treatment and
relapse, isolates with cross-resistance to BDQ and CFZ (Rv0678
mutation) were observed in a Tibetan patient [52]. Therefore, it is
recommended that if a previous anti-TB regimen with CFZ was
used, susceptibility to BDQ should be ensured before starting a
BDQ-containing regimen [53].
In 2019, the emergence of low-level BDQ-resistant strain in a
50-year-old patient with XDR-TB was reported. The baseline
isolate was susceptible to BDQ by MGIT (Mycobacterium Growth
Indicator Tube), but the colorimetric resazurin microtitre assay
(REMA) showed increased MICs up to 8-fold compared with the
baseline isolate at weeks 22, 32, 42 and 64 of treatment [54]. In a
retrospective study conducted by Ghajavand et al., MICs and
possible mutations related to resistance were examined in 24 M.
tuberculosis strains from patients previously receiving a BDQ-
containing regimen. The BDQ MIC was 0.25 mg/L in 15 isolates.
Moreover, one pre-XDR isolate and four (one MDR, one pre-XDR
and two XDR) isolates had MICs of 4 mg/L and 8 mg/L, respectively.
Whole-genome sequencing revealed that two isolates harboured
non-synonymous mutations in mmpl5 (efflux pump) and one
isolate showed rv1979c M245L mutation [50].
In Pakistan, Ghodousi et al. evaluated 70 M. tuberculosis strains
from 30 patients previously administered BDQ-containing regi-
mens. The baseline strains were susceptible to BDQ, but five
patients acquired resistance to BDQ and an increase in MICs
(range, 0.125 to >0.5 mg/L) during treatment. In addition, they
examined specific mutations in Rv0678 contributing to elevated
BDQ MICs in cases failing therapy [55]. In 2016 in Russia, Zimenkov
et al. studied 85 isolates from 27 patients with decreased
susceptibility to BDQ (MIC  0.06 mg/L). They documented nu-
merous cases with strains with increased MICs of BDQ before
treatment and high MICs of BDQ associated with mmpR geneAnother mechanism contributing to the development of
esistance to CFZ and BDQ is non-target mutations in pepQ
Rv2535c, a putative Xaa-Pro aminopeptidase). Point mutation in
epQ is believed to be a potential cause of BDQ or CFZ resistance in
. tuberculosis isolates. These mutations were selected in mice by
reatment with BDQ. The pepQ mutations were associated with5
mutation [56]. Like other drugs, the occurrence of BDQ resistance
is frightening because it may prompt the fast failure of this novel
antibiotic. As a consequence, detection of BDQ resistance
mechanisms and an increase of standardised antibiotic suscepti-
bility testing will help to direct treatment and diminish the risk of
resistance.1
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4.1. Synergism of bedaquiline with delamanid
There are concerns about possible additive cardiac toxicity for
BDQ plus delamanid (DLM) combination therapy [57]. It has
recently been reported that these drugs have a good effect on MDR/
XDR-TB patients particularly when four active antibiotics cannot
be involved in a regimen [57–60].
The first case of XDR-TB treated with co-administration of DLM/
BDQ with CFZ was reported in 2016 [61]. DLM, a bicyclic
nitroimidazooxazole agent, prevents the synthesis of mycolic
acids in mycobacteria [62,63]. The patient was resistant to second-
line drug treatment, so there were no resources currently available
for this patient and combination therapy was started. The
recommended regimen was interrupted after eight doses of BDQ
with DLM administration because there were ongoing concerns
regarding QTc prolongation. The patient was closely monitored and
an electrocardiogram (ECG) was repeated biweekly [61]. A QTc
interval >500 ms is considered a risk factor for severe arrhythmia,
and if this sign is seen in patients, clinicians should interrupt
treatment and consider the patients carefully [64]. Nearly 1 month
later, BDQ was restarted and revealed a negative sputum smear and
culture alongside correction in electrolytes, serum albumin and
ECG QT wave interval at 2-months follow-up [61].
Furthermore, in 2016 Lachâtre et al. reported favourable
clinical, microbiological (smear and culture) and radiological
responses in a 20-year-old man with pulmonary TB who had
received BDQ plus DLM at 6-month follow-up. The combination of
two drugs had no side effects such as QT interval prolongation [65].
In another study, five patients living in Russia, India and the
Netherlands received BDQ with DLM in combination. The patients
had either drug treatment failures or relapsed during their
treatment and were resistant to at least five anti-TB drugs.
Continuation of the suggested regimen showed the sputum and
cultures of four patients converted to negative after 18–435 days
and 28–218 days, respectively, however one patient died from
respiratory failure. For three patients the QTcF intervals remained
normal and only two patients had brief abnormalities in their heart
performance that quickly normalised [64].
Although DLM and BDQ combination appears to be helpful in
severe, almost untreatable, XDR-TB cases, some concerns about
potential cardiac side effects (QT interval prolongation) remain
contested [66]. Recently, a retrospective cohort study was
performed in Armenia, India and South Africa to assess the
efficacy and safety of DLM and BDQ combination therapy for MDR-
TB. All laboratory tests related to drug safety such as haemoglobin/
electrolyte measurement and ECG monitoring were carried out
regularly and suggested that using combination therapy with BDQ
and DLM had no additive or synergistic QTcF-prolonging effect.
Moreover, efficacy assessment of the combination determined by
negative sputum culture showed that all patients in this study had
a documented negative culture at 6 months [67].
At the present time, we can consider BDQ and DLM combination
as a novel anti-TB treatment for MDR and XDR strains that needs
close monitoring and adequate management of patients during
their co-administration to consider potential cardiological side
effects [59,61,66].
4.2. Synergism of bedaquiline with pyrazinamide
reserves [69]. More than one decade ago, the first study of BDQ
efficacy in mice showed that the combination of BDQ and PZA with
another first- or second-line anti-TB drugs diminished the bacterial
load to change the lung culture to negative after 2 months of
treatment [70]. In other parallel study undertaken in 2007, the BDQ
and PZA combination had the most effective results compared with
other combinations. Co-administration of BDQ and PZA converted
100% of mice to culture-negative after 2 months of treatment [71].
The efficacy of BDQ and PZA treatment has been determined for
BALB/c, Swiss and C3HeB/FeJ mice infected with M. tuberculosis
and decreased the bacterial load after 4 weeks of treatment [68].
Furthermore, the combination of BDQ and PZA revealed strong
synergy and increased bactericidal activity in vitro. Inhibition of
energy metabolism caused by BDQ combined with the front-line
drug PZA resulted in a synergistic effect to reduce Mycobacterium
bovis BCG used as a model [69]. In a randomised clinical trial of 105
patients, the antimycobacterial activity and pharmacokinetics of
different combinations including BDQ, PZA and other supplemen-
tary first-line agents was evaluated as 14-day early bactericidal
activity (EBA), expressed as the rate of change in log10 CFU counts
over 14 days of treatment (EBACFU0–14). The highest mean
EBACFU0–14 estimate was found with the BDQ, PZA and
pretomanid (PA-824) combination regimen, which had activity
identical to the current standard anti-TB regimen. The authors
suggested longer clinical studies determining its efficiency as a
potential new TB treatment regimen [72]. Another randomised
EBA study performed by Diacon et al. on treatment-naive, drug-
susceptible patients with uncomplicated pulmonary TB who
received BDQ, BDQ + PZA, PA-824 + PZA, BDQ + PA-824, PA-
824 + moxifloxacin + PZA or standard anti-TB treatment as a
positive control. Although the mean 14-day EBA of PA-824 + moxi-
floxacin + PZA was significantly higher than the other combina-
tions, the onset of activity of BDQ was delayed with an inflection
point at 6.5 days. This result may be explained by the fact that PZA
increases the activity of BDQ resulting in greater activity of BDQ
and PZA than BDQ alone. Addition of PA-824 to BDQ seemed to
have little if any effect on the activity of BDQ, albeit without
causing clear antagonism [73].
As a conclusion, a possible explanation for this synergism might
be that PZA interferes with the proton motive force and membrane
integrity, so it indirectly inhibits ATP synthase and has a synergistic
function with BDQ [71]. Thus, addition of BDQ to PZA can
accelerate bacterial elimination and may help minimise the
treatment duration for patients [74].
4.3. Synergism of bedaquiline with cephalosporins
A novel approach in pharmaceutical development is ‘new uses
of older drugs’. Due to the high cost of developing a new drug and
the appearance of resistance mechanisms in Mycobacterium,
administration of existing drugs is arousing the interest of
pharmaceutical companies. Cephalosporins, which disrupt syn-
thesis of the peptidoglycan layer of the bacterial cell wall, have a
synergistic effect with new anti-TB drugs. So they can be
repurposed in new combination TB regimens.
An in vitro synergy assay of cefradine and faropenem with a
panel of anti-TB drugs including BDQ was performed for M.
tuberculosis H37Rv strains. The fractional inhibitory concentration
of each drug in the combination was calculated. Isobologram
curves showed a strong synergistic interaction of cephalosporinsPyrazinamide (PZA) is a highly effective drug that targets vital
bacterial process such as the proton motive force and ribosomal
translation [68,69]. Due to the role of BDQ as an ATP synthase
inhibitor, it seems their combination can suppress bioenergetic
functions and both drugs potentially deplete cellular energy52with BDQ, DLM and PA-824 but not with isoniazid, ethionamide,
aminoglycosides or fluoroquinolones [75]. The authors did not
elucidate the precise mode of action of these synergistic
combinations, therefore further work is required to unravel the
molecular mechanisms behind them and to facilitate adding
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Pretomanid (PA-824), a nitroimidazo-oxazine, has shown
ignificant bactericidal activity alone and in combination with
ovel agents both against replicating and non-replicating strains of
. tuberculosis [76,77]. Its activation pathway either diminishes
ntracellular ATP or inhibits cell wall mycolic acid synthesis
comparable with the activity of isoniazid) [78]. Several studies
ave investigated the interaction of BDQ and PA-824 as an anti-TB
ombination in a mouse model and also in patients with
ulmonary TB.
Evaluation of several beneficial anti-TB agents against intracel-
ular M. tuberculosis was performed on whole blood culture.
ombination of BDQ, sutezolid (an oxazolidinone) and SQ109 (an
thambutol analogue) had a significant additive effect, whereas
dding PA-824 to those regimens containing BDQ or sutezolid
esulted in less than synergistic effect or antagonism [79]. The
ntagonistic effect of PA-824 with BDQ was examined in several
tudies and revealed the activity of BDQ plus PA-824 was the same
s the first-line regimen during 2–3 months, however over the first
onth the combination had lower efficacy than BDQ alone
76,80,81].
On the other hand, in phase IIa clinical trials of new anti-TB
rugs, PA-824 was combined with other agents for patients with
rug-susceptible isolates. Among the different combinations, the
A-824, moxifloxacin and PZA group had the most favourable
esults compared with BDQ alone, BDQ with PA-824, or PZA [73].
Moreover, a double-blind, randomised assessment of multiple-
gent combinations was performed on 15 patients with pulmonary
B. The 14-day EBA was assessed as decreasing CFU of M.
uberculosis per millilitre of sputum. The most effective combina-
ion was PA-824 + moxifloxacin + PZA, which was significantly
igher than the other groups. It is important to note that a regimen
acking isoniazid and rifampicin would provide a beneficial step
owards novel regimens with low interaction potential. Besides the
ctivity of BDQ + PA-824 was identical to isoniazid + rifampi-
in + PZA + ethambutol, which was lower than PA-824 + moxiflox-
cin + PZA [73].
.5. Synergism of bedaquiline with pretomanid plus linezolid
Linezolid (LZD), a first-generation oxazolidinone antibiotic, is
ffective for treatment of chronic pulmonary XDR-TB [82,83]. A
rospective randomised trial demonstrated bacteriological con-
ersion in XDR-TB patients administered a reduced LZD dosage
300–600 mg/day) [84].
A study published in 2016 found that the contribution of LZD to
DQ–PA-824 had sterilising activity in a mouse model of TB. In this
tudy, the efficacy of BDQ and PA-824 with LZD singly and as a
ombination in a three-drug regimen was examined. All two-drug
ombinations had lower activity compared with the activity of the
hree-drug combinations of BDQ–PA-824 plus LZD at 2 months
80].
.6. Bedaquiline interactions with antiretroviral drugs
Drugs that inhibit cytochrome P450 3A4 (CYP3A4) could result
n increased concentrations of BDQ, which could increase risk
oxicity, whereas drugs that induce CYP3A4 could result in reduced
oncentrations of BDQ. The WHO has suggested first- and second-
Various studies have shown only modest effects of lopinavir/
ritonavir and nevirapine on BDQ exposure [4,85].
Ritonavir-boosted lopinavir (LPV/r) decreased the clearance of
BDQ and its M2 metabolite to 35% [relative standard error (RSE),
9.2%] and 58% (RSE, 8.4%), respectively. Approximately two-fold
(M2) and three-fold (BDQ) increases in exposure during chronic
treatment with LPV/r are expected and dose alterations are
recommended for evaluation. Safe, effective BDQ dosing for
patients with MDR-TB receiving antiretrovirals is essential. The
findings of this study show that BDQ can be co-administered with
nevirapine without dose adjustments [86].
Another antiviral drug, efavirenz (EFV), induces CYP3A4, the
metabolic enzyme responsible for BDQ biotransformation. Due to
the induction of CYP3A4 by EFV, the drugs are predicted to interact.
A study by Svensson et al. showed that during EFV co-
administration, simple adjustments of the standard regimen can
preclude reduced exposure to BDQ without increasing exposure to
M2. Assessment of adjusted regimens is important to ensure
proper dosing for HIV-infected TB patients receiving an EFV-based
regimen [87]. Also, in a phase I study, 600 mg EFV once daily
reduced exposures of single-dose BDQ by 18% and increased the
maximum concentration (Cmax) of M2 by 89% [88].
5. Pharmacokinetics and pharmacodynamics
The time to peak concentration and plasma half-life of BDQ are
4–6 h and 24–30 h, respectively. However, the terminal elimina-
tion half-life is much longer. This antibiotic can conjugate with
blood transport proteins, is metabolised by the liver enzyme
CYP3A4 to its main metabolite M2 and is eliminated in the faeces
[89,90]. In a study by Dhillon et al., intracellular activity in a J774
macrophage-like cell line and in primary mouse peritoneal
macrophages had little or no static phase, so that the bactericidal
kill was apparent by 5–7 days probably due to decreased bacterial
ATP levels. Overall, the intracellular activity of TMC207 was
obviously greater than its extracellular mainly because the primary
static phase was shorter [91].
Mild-to-moderate renal disorders have no influence on the
pharmacokinetics of BDQ. It is unnecessary to adjust medication
regimens for people with moderate hepatic or renal impairment,
but we recommend caution for patients with severe renal or
hepatic impairment. Several factors such as age, sex, body weight
and concomitant HIV infection have not been reported to affect the
pharmacokinetics of BDQ. Experiments showed that among
different ethnicities, subjects of Black ethnicity had lower
concentrations of BDQ than other races [2].
The sterilising activity of BDQ has been studied in guinea pigs
and mouse models of TB infection and the results showed that the
sterilising activity BDQ alone and in combination against drug-
susceptible and several MDR-TB. It was also observed that BDQ
interacts with histamine type 2 receptors (87%), sodium channels
(71%) and dopamine transporters (54%), while there is low
potential for interaction with either transport binding sites or
other receptors (including, but not limited to, cholecystokinin,
angiotensin, opioid, norepinephrine transporters or chloride
channels) [92,93].
6. Adverse events
Antibiotics used for the treatment of drug-resistant TB are
ine antiretroviral drugs that may affect BDQ exposure by
nhibiting and/or inducing CYP3A4.
The protease inhibitor lopinavir/ritonavir and the non-nucleo-
ide reverse transcriptase inhibitor (NNRTI) nevirapine are,
espectively, a potent inhibitor and moderate inducer of CYP3A4.5
associated with high rates of side effects and are often poorly
tolerated. Today with regard to the shortcomings and limitations
that exist in the treatment, it is important to note that BDQ has an
elimination half-life of 5.5 months owing to a combination of a
high tissue distribution and long plasma half-life [3].3
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headache, dizziness, vomiting and arthralgia. In one study, 47
MDR-TB cases received either placebo (24 cases) or TMC207 (23
cases) in combination with a standard five-drug, second-line anti-
TB regiment. In this study, nausea occurred significantly more
frequently in the TMC207 group compared with the placebo group
(26% vs. 4%; P = 0.04). But overall side effects were similar in the
two study groups. The most common side effects observed
included unilateral hypouricemic deafness, haemoptysis, limb
pain, rash, arthralgia, nausea and chest pain [94].
One of the major concerns of the FDA Committee on BDQ
safety is the unexplained increase in BDQ mortality in a
randomised controlled trial [95]. Adverse reactions of BDQ in
a study by Guglielmetti et al. were mostly mild [96]. The
percentage of subjects who experienced a 60 ms increase in
QTcB during therapy (20%) was higher than in previous studies
and, as found in the C209 Trial, was more marked in subjects
receiving BDQ in association with CFZ. Although short-term
safety results appear promising, careful and regular follow-up of
patients for severe side effects is important even after
discontinuation of the drug. This is of much significance for
the combination of BDQ with other anti-TB drugs [96,97]. One of
the most common side effects of BDQ observed in patients is
increased QTc interval on the ECG [98]. Approximately 11.4% of
cases taking BDQ died during clinical trials compared with 2.5%
of those taking placebo. Because this drug carried significant
risks, it is necessary to use it only in patients who have no other
treatment options [99]. According to other results, among 45
MDR-TB patients, severe and serious adverse events were
recorded in 27 (60.0%) and 7 (17.8%) of cases, respectively.
Among 44 patients, the most frequent adverse effects were
gastrointestinal side effects (32; 71.1%), otovestibular im-
pairment (25; 55.6%) and peripheral neuropathy (18; 40.9%).
A measured Fridericia-corrected QT interval (QTcF) >500 ms was
recorded 11% of individuals, but neither arrhythmias nor
symptomatic cardiac side effects were observed. BDQ was
discontinued in 3 patients (6.7%) following QTcF prolongation.
The study also found no significant differences in outcomes or
side effects between patients treated with standard long-term
BDQ. Regimens containing BDQ achieved excellent results in a
large proportion of patients. Long-term treatment with BDQ was
generally well tolerated in this group [100].
Furthermore, BDQ has a black box warning that it can affect the
sudden electrical activity of the heart and also prolong the QT
interval, which can lead to an abnormal and possibly lethal heart
rhythm [99].
7. Clinical treatment
7.1. Use in multidrug-resistant tuberculosis (MDR-TB) cases
Conventional regimens for treating MDR TB are not the answer
today, as studies have shown at least 20 months of treatment with
a combination of second-line drugs is harmful, expensive and also
little more efficacious than drugs applied to treat drug-susceptible
TB. In a cohort study, just 50% of the group of patients observed
responded well to treatment owing to the high frequency of death
(16%), treatment failure (10%) and a lack of follow-up (16%) usually
related to adverse drug reactions, among others [92].
Belarus in Eastern Europe was one country with concerning
In June 2013, the WHO issued a temporary policy manifesto to
provide instruction on the availability of BDQ in qualified patient
groups [3]. The temporary policy is based on a document
evaluation and advice by a specialist group convened with the
WHO/Stop TB Department in Geneva, Switzerland, and resulted in
the commendation that BDQ may be added to regimens in the
adult group with pulmonary MDR-TB (conditional commendation,
very low assurance in the assessment of effects).
Because of concerns about the prevalence of drug resistance in
this group of patients, especially resistance to fluoroquinolones or
second-line injectable drugs (kanamycin, amikacin, capreomycin),
BDQ may have a major function in strengthening the regimen,
increasing the number of drugs that may be effective to at least
four, and preventing the development of additional resistance and
progression to XDR-TB [36].
In a study conducted in 15 countries among people in aged 18–
65 years who have recently been diagnosed with pulmonary MDR-
TB, 160 persons were a randomised in a clinical trial to receive BDQ
or placebo with a five-drug MDR-TB background regimen. The
average period to culture conversion was for 83 days [95%
confidence interval (CI) 56–97 days] in the BDQ group vs. 125
days (95% CI 98–168 days) in the placebo group.
Applying Cox symmetrical risk pattern (equal to lung cavitation
and pooled centre) there was higher chance of rapid culture
conversion in the BDQ arm compared with the placebo arm
(hazard ratio = 2.44, 95% CI 1.57–3.80; P < 0.0001). The proportion
of subjects with culture conversion at Week 24 (secondary efficacy
endpoint) was 78.8% in the BDQ arm versus 57.6% in the placebo
arm (P = 0.008) [13].
The drug has been approved relying on the results of a phase II
trial. The study was in the form of a randomised clinical trial to test
the protection and effect of BDQ when added to background
regimen in recently recognised cases with pulmonary MDR-TB
administrated. The results of the first experiment showed [98] the
superiority of TMC207 (48%) to the standard drug regimen for this
disease resulting in rapid conversion to a negative sputum culture
compared with the placebo group (9%). The mean percentage of
negative smear for fast acid bacilli the for TMC207 and placebo
groups was 77% and 57% at Week 4 and 84% and 68% at Week 8,
respectively.
In the second trial [101], the average time for sputum culture
conversion for TMC207 was about 78 days compared with 129 days
for placebo. Those receiving TMC207 were at a lower risk of
acquisition of additional drug resistance during the entire follow-
up period. The results showed that the percentage of side effects in
cases who received BDQ was 82.6%, similar to those who received
placebo (79.2%).
The results of a study showed that BDQ and DLM were safe and
useful for remedying MDR-TB, with an early clue of consecutive
administration of these two medicines as a viable therapeutic
strategy for patients when enough therapeutic regimen cannot be
manufactured. Among 55 participants who showed positive
sputum cultures at the onset of BDQ and/or DLM treatment, 39
(70.9%) achieved sputum culture conversion within a median of
119 days. Treatment was halted in four cases (6.6%) because of
prolonged QTcF [102].
Also, another study in 2017 by Achar J et al. described 27
children and adolescents aged <18 years who were taking BDQ for
the treatment of MDR-TB. The results of their study showed a good
therapeutic response and no termination because of adversestatistics regarding MDR-TB. The results of a previous study
showed that MDR-TB was found in 35% of new cases and 75% of
previously treated cases. Regarding the few patients with TB who
undertake drug susceptibility testing in most high-outbreak
countries, it is probable that the frequency of MDR-TB is higher
than reported [29].54effects [103].
7.2. Use in drug susceptible tuberculosis cases
After the first therapeutic trials aimed at assessing single drugs


























































S. Khoshnood, M. Goudarzi, E. Taki et al. Journal of Global Antimicrobial Resistance 25 (2021) 48–59hat a single drug was not enough to prevent the development of
rug-resistant TB. The next therapeutic challenge was to combine
his goal with a reduction in the long treatment duration [104].
vailable anti-TB regimens are expensive and long-term, require
igh adherence, and are undermined by a high frequency of
dverse effects, thus leading to low rates of treatment success. To
mprove adherence to treatment, in 2016 a shorter TB regimen was
uggested by the WHO under specific microbiological and clinical
onditions. Although new anti-TB drugs that may permit
hortening of the duration of TB treatment and improve its
utcome are favourable, in the last 50 years only BDG and DLM
ave been confirmed for MDR-TB treatment. Research should look
or easily available, well tolerated and short regimens to get closer
o the WHO aim. BDQ is an important drug to shorten the MDR-TB
nd XDR-TB regimen; in fact, a phase 3 study aimed at evaluating
he efficacy and safety of a BDQ regimen associated with linezolid
nd pretomanid in adult individuals with pulmonary XDR-TB
ntolerant to conventional treatment or non-responsive MDR-TB is
urrently recruiting participants [105].
.3. Use in latent tuberculosis infection (LTBI)
LTBI is defined as the situation of continuing immune response
o stimulation by M. tuberculosis antigens with no record of
linically active TB. In many high-income and developed countries,
TBI has been a crucial part of TB control programmes for decades
ecause it was first identified that progression of the disease could
e prevented in guinea pigs and humans [106].
The bactericidal activity of BDQ in liquid culture medium begins
ith a bacteriostatic phase lasting 7 days, and afterwards a
ontinued dose-related bactericidal phase. However, studies have
hown that the intracellular activity of BDQ is greater than its
xtracellular activity because the preliminary static phase was
horter or absent.
BDQ may affect ongoing treatment for LTBI. This is especially
rue for LTBI therapy for close contacts of patients with drug-
esistant TB. Unfortunately, there is no practical and standard
pproach to treating LTBI among patients with MDR/XDR-TB (DR-
TBI). In a study in a mouse model, BDQ displayed bactericidal
ctivity against dormant (non-replicating) tubercle bacilli with
ubstantial sterilising activity and may enable treatment of DR-
TBI in 3–4 months [107,108].
Another study by Lanoix et al. used three drugs alone and in
ombination in an experimental paucibacillary LTBI chemotherapy
odel using BALB/c and C3HeB/FeJ mice immunised with a
ecombinant strain of M. bovis BCG (rBCG30) and then challenged
ith a low-dose aerosol of M. tuberculosis H37Rv. The regimens
ested included BDQ, PA-824 (Pa), sutezolid (PNU), and/or one of
wo fluoroquinolones. Control mice received rifampicin or isonia-
id. The results showed that in BALB/c mice BDQ-containing
egimens and the Pa-PNU combination were the most active tested
egimens and were at a minimum as impressive as rifampicin. The
esults confirmed the potent activity of BDQ previously observed in
ALB/c mice and highlight Pa alone or in combination with either
NU or a fluoroquinolone as worthy of assessment in clinical trials
f MDR-LTBI [109].
.4. Use in difficult-to-treat nontuberculous mycobacteria (NTM)
fections
DLM showed high MICs for all NTM except M. kansasii. BDQ had
low MICs for MAC, M. kansasii, M. abscessus and Mycobacterium
massiliense. This antibiotic also had low MICs against macrolide-
resistant NTM. The results of their study showed that BDQ had a
good in vitro effect against pathogenic NTM, but DLM did not. BDQ
has the potential to be an effective antibiotic for treatment
macrolide-resistant NTM pulmonary disease [110]. In 2020, Erber
et al. reported the first reported case of successful in vivo use of
BDQ for infection caused by M. fortuitum [111].
7.5. Use for immunodeficient patients
TB treatment has been completely clinical for a long time, and
after 2008, based on phase 2 clinical trials, three new anti-TB drugs,
namely BDQ, DLM and PA-824, were introduced [112]. At birth,
human serum albumin (HSA) concentrations are approximately
the same as in adults (75–80%), while alpha-1-acid glycoprotein
(AAG) is initially half the concentration in adults. As a result, the
rate of drug binding to HSA is closer to that of adults than for other
drugs that bind more to AAG. A model that incorporates the
fraction unbound in adults and the ratio of binding protein
concentration between infants and adults has successfully
predicted the unbound fraction in infants and children [113].
Svensson et al. reported a study on the pharmacokinetics of
BDQ and its metabolite M2 in 335 patients with MDR-TB receiving
24 weeks of BDQ in addition to a longer individualised history
regimen. Semi-physiological models described changes in weight
and albumin over time. It correlated weight and albumin,
increasing since the beginning of remedy, and affecting BDQ and
M2 plasma disposition [114].
Applying a population pharmacokinetic model, the results of
long-term co-administration of BDQ and efavirenz, a CYP3A
inducer, was assessed. Among healthy adult volunteers, it was
observed that a single dose of efavirenz alone minimally affected
BDQ pharmacokinetics. Nevertheless, efavirenz could decrease
concentrations of BDQ and its main metabolite by up to 52%
following long-term co-administration [2].
Among HIV-positive patients with MDR TB, higher mortality
rates are often observed. Efavirenz and nevirapine also induce
CYP3A4. Ritonavir, a further promoter of protease suppressants, is
a CYP3A4 inhibitor. When efavirenz is given with a single dose of
BDQ, the concentration of BDQ is reduced by about 20%. About 50%
reduction is predicted when mathematical modelling is evaluated
to assess BDQ concentrations [88].
Concomitant use of ritonavir-boosted lopinavir (LPV/r) with
BDQ may be troublesome. Albeit a single-dose drug–drug
interplay study showed just a light rise in concentrations of
BDQ and its basic metabolite, it is probably that remarkable
reposition of BDQ and its metabolite will arise with extended
usage of BDQ and LPV/r. As the clinical effects are not clear when
using LPV/r and BDQ, one should use this combination with
extreme caution and only in closely monitored conditions if no
other options are available [115].
In a study of 91 drug-resistant TB patients followed-up until
August 2014, 54 (59%) were infected with HIV. The average CD4
count was 239 cells/mL and all cases were receiving antiretroviral
therapy at the beginning of BDQ treatment; 33 patients had XDR-
TB, 41 were pre-XDR-TB with resistance to a fluoroquinolone and
17 were pre-XDR-TB with resistance to an injectable. Of the 91
cases in the study, 58 (64%) completed 24 weeks of BDQ, 28 (31%)The prevalence of NTM pulmonary disease is increasing
lobally. Mycobacterium kansasii, M. abscessus and Mycobacterium
vium complex (MAC) are the most common NTM. Azithromycin
nd clarithromycin are key antibiotics for treating NTM pulmonary
isease. Previous studies have suggested that the MICs of BDQ for
. tuberculosis were very low. In a study conducted by Kim et al.,5
were still on BDQ, 3 (3.2%) were lost to follow-up, 1 patient died
and 1 patient was withdrawn following atrial fibrillation. Among
63 cases in the follow-up study for 6 months, 48 (76%) had either
culture-converted or remained culture-negative after starting of
BDQ. QTcF was monitored every month and exceeded 500 ms in
three participants, which resolved in all three [116].5
S. Khoshnood, M. Goudarzi, E. Taki et al. Journal of Global Antimicrobial Resistance 25 (2021) 48–59Diabetes and hypoglycaemic agents may affect anti-TB treat-
ment. Information supporting this outcome are reported just for
standard anti-TB therapies. For diabetics, the new MDR-TB drugs
Sirturo1 (BDQ) and Deltyba1 (DLM) are recommended when
another effective treatment regimen cannot be provided. There is
particular concern about the consumption of BDQ and DLM in
diabetic cases up the age of 65 years as well as in patients with
severe renal or hepatic impairment or electrolyte imbalance.
Simultaneous consumption of BDQ and DLM with insulin
analogues as well as other hypoglycaemic factors that prolong
the heart rate-corrected QT interval, such as sulfonylureas and
glinides, may boost this adverse response. Hepatic-related side
effects may be more likely to occur when these drugs are combined
with thiazolidinediones and acarbose [117].
The WHO recommends BDQ in pregnant women and children
below 18 years of age, but the US Centers for Disease Control and
Prevention (CDC) said it could consider them it in these
populations and in cases with extrapulmonary disease. This drug
is considered in the FDA class B pregnancy category. It is not yet
known whether BDG and its metabolites are excreted in human
breast milk, although results show that milk is concentrated in rats.
Both the CDC and the FDA raised concerns and stressed the need
for critical oversight of several specific diseases, including liver
disease, heart disease, and alcohol and drug abuse [118].
8. Other considerations for bedaquiline therapy
Based on the FDA strategies, BDQ was prioritised to patients and
rapid determination and orphan-product designation of this drug
was granted. This drug was approved a part of combination therapy
to treat adults with pulmonary MDR-TB where other suitable
options are not available [99]. In 2013, the WHO and CDC issued
interim recommendations for the use of this drug for the treatment
of MDR-TB patients [119]. BDQ should be prescribed for the
treatment of patients with MDR-TB, if an effective strategy with
PZA and four second-line medicines, as suggested by the WHO
protocol, otherwise cannot be designed. It is also suitable to treat
MDR-TB with referenced resistance to any fluoroquinolone. The
suggested dose is 400 mg daily for 2 weeks, followed by 200 mg
three times a week for 22 weeks. To maximise efficiency and
absorption, the WHO recommended intake with food. It should
also not be prescribed for over 6 months, while the CDC
recommended that treatment be considered on a case-by-case
basis for over 24 weeks unless an efficient regimen is otherwise
prescribed [120].
The introduction of BDQ to patients at country level neces-
sitates the consideration of several of concerns of public-health
significance, including: wide availability; the recognition of fixed-
dose or optimal combinations to be used according to the type of
TB; and the expected effects and adverse events of the drug on
patients’ eligibility criteria. Additionally, it is necessary to certify
programmatic practicability and cost-effectiveness of BDQ. India’s
success rate for MDR-TB was lower than 50%, so it accounts for one-
quarter of the world’s MDR-TB. Since 2015, BDQ was approved in
India for use under a conditional access programme. A BDQ
compassionate programme suggested that use of BDQ with
additional monitoring may be safe and effective even in the field
setting because of higher and faster culture conversion rates
among MDR/XDR-TB patients and a lower toxicity profile when
BDQ was used with a background regimen [121].
addition, the cure rate, treatment success rate and the death rate
(excluding Georgia and Armenia, n = 351) at the end of follow-up
(18–24 months) were 63.8% (95% CI 57.8–69.4; 223/351), 69.1%
(95% CI 59.1–77.6; 234/351) and 10.6% (95% CI 3.80–20.0; 37/351),
respectively [122].
Suitable financial funds should be allocated to warrant
successful and justifiable implementation of BDQ introduction
at country level. The WHO planning and budgeting tool for TB
control activities is a helpful resource to estimate the necessitated
budget at country level [123].
A budget impact analysis conducted on managing MDR-TB in
South Africa reported that despite the high cost of BDQ, a BDQ-
based shortened regimen for the treatment of MDR-TB will result
in improved treatment outcomes and cost savings for South Africa.
Also, introducing BDQ to long-course treatment will result in a 5%
increase in the cost per successful outcome (expected to be US
$7739) in 2023 [124].
In a cost-effectiveness analysis, Ionescu et al. [125] compared
the cost effectiveness of BDQ versus injectable-containing drug-
resistant tuberculosis regimens (short-course regimen and long-
course regimen) in India, Russia and South Africa. Across all
countries, BDQ-containing regimens were most cost effective
based on cost per treatment success compared with injectable-
containing regimens, decreasing these in short-course regimen by
18–20% and in long-course regimen by 49–54%. Average cost
effectiveness ratios of BDQ containing regimens are lower.
9. Conclusion
Many articles have been published on the promising results of
BDQ in MDR-TB until now. However, it seems that more studies are
still needed to draw conclusions. The most important issue about
BDQ-containing regimens is precise consideration of resistant
strains by specific drug susceptibility testing. Moreover, a
comprehensive surveillance system is required for the evaluation
of adverse effects and mechanisms of resistance and co-resistance
with other anti-TB drugs. Therefore, efforts to appropriate BDQ
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